← Back to patent-cliff list
ACR-2316
Tier C — Watch / tradeACR-2316
Acrivon Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：WEE1, PKMYT1
Indications (approved)：Solid tumour
Regional status
US
Phase II
2024-10-08
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ACR-2316?
Approved indications include: Solid tumour.
When does the ACR-2316 patent expire?
No public expiry year is available for ACR-2316 yet; this page updates once verified.
How do I get a quote for ACR-2316 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01